論文・技術情報追加のお知らせ

①Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.

ヤンセン社COVID-19ワクチンのベネフィット・リスク評価検討

対象DB：VAERS

②Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events.

薬理ネットワークモデルに基づくベイズ型シグナル検出アルゴリズムの開発と検証

対象DB：FAERS

③Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System.

エンテカビルとアデホビル・ジピボキシルに関連する妊娠中有害事象調査研究

対象DB：FAERS

④Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.

GLP-1受容体作動薬の使用に伴う消化器系リスク比較研究

対象DB：FAERS

⑤Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.

COVID-19ワクチン接種後の血小板減少症候群を伴う血栓症症例調査研究

対象DB：VAERS

⑥Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab.

がん患者におけるペムブロリズマブによる免疫関連有害事象関連因子探索研究

対象DB：FAERS

⑦Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.

インフルエンザワクチンの市販後安全性サーベイランス

対象DB：VAERS

⑧Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT((R))) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review.

ボツリヌス毒素ヘプタバレント安全性プロファイリング

対象DB：CVAR